RYAN ARTHUR F 4

What Happened
Ryan Arthur F, a director of Regeneron Pharmaceuticals (REGN), sold a total of 100 shares in multiple open‑market transactions on March 2, 2026. The sales were executed at prices ranging roughly from $777.46 to $789.28, for an aggregate proceeds of approximately $78,548. These were disposals (sales), not purchases.

Key Details

• Transaction date: March 2, 2026; Form 4 filed March 3, 2026 (timely — within SEC filing window).
• Total sold: 100 shares for total proceeds of ~$78,548. Individual trade prices ranged about $777.46–$789.28.
• Transaction type/code: S = Sale (open market).
• Footnotes: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted October 31, 2025 (F1). Several footnotes report volume‑weighted average prices for grouped sales and note more detailed per‑price breakdowns are available upon request (F2–F13).
• Shares owned after the transactions: Not specified in the provided excerpt of the filing.

Context
These sales were reported as part of a predetermined 10b5‑1 plan, which is a common mechanism insiders use to sell shares on an automated schedule and is generally viewed as a routine disposition rather than an ad hoc signal about company prospects. The filing shows no option exercises, gifts, or tax‑withholding share transfers—only open‑market sales.